S sequencing and functional assays, happen to be developed to establish the mutation status of TP53 as it applies to CRC. In preceding studies, perioperative variations in serum anti-p53 antibody levels happen to be shown to predict OS (Table 4) [12, 144]. However, only the sequencing information were correlated together with the degree of chemoresistance (Table 5) [4, 11, 251]. Anti-p53 antibody has low sensitivity in CRC but is almost 100 certain for malignancy. Therefore, we think anti-p53 antibody measurement is appropriate and cost-effective for screening a high-risk population and for postoperative cancer surveillance as a guide for earlier detection of recurrence [29]. This study had some limitations. Because of its retrospective and single-center nature, an unknown bias could exist within the findings. Moreover, we didn’t measure TP53 mutation employing sequencing process that is one of the key solutions of detect TP53 mutation. When we assess the partnership in between TP53 gene mutation and chemoresistance in mCRC sufferers, we should use other methodologies for example sequencing and functional assays, aside from the anti-p53 antibody status.sarcoma viral oncogene homolog B; MEK: Mitogen-activated protein kinase kinase; ERK: Extracellular signal-regulated kinase; OS: Overall survival; PFS: Progression no cost survival; Bev: Bevacizumab; RESIST: Response evaluation criteria in solid tumors; ELISA: Enzyme-linked immuno- sorbent assay; ORR: All round response rate; NA: Not out there; HR: Hazard ratio; CI: Self-confidence Interval; VEGF: Vascular endothelial growth element; MHC: Main histocompatibility complicated. Competing interests S. Matsusaka: commercial study grant, Taiho Pharmaceutical Co., Ltd. E. Shinozaki: honoraria from speakers bureau, Taiho Pharmceutical Co., Ltd., Chugai Pharmceutical Co., Ltd., Yakult Honsha Co., Ltd., Bristol-Myers Squibb, Takeda Pharmceutical Co., Ltd. N. Mizunuma: commercial study grant, Taiho Pharmaceutical Co., Ltd., Chugai Pharmceutical Co., Ltd., Yakult Honsha Co., Ltd., Bristol-Myers Squibb, Takeda Pharmceutical Co., Ltd., Merck Serono Co., Ltd., ONO Pharmaceutical CO., LTD., Bayer Yakuhin CO., LTD. All remaining authors have declared no conflicts of interest. Authors’ contributions The original manuscript was written by HO. HO and ES and YK and MO and MO and MS and SM and KC and NM performed chemotherapy for mCRC. NY performed immunostaining with anti p53 protein antibody on formalinfixed paraffin-embedded fragments. All authors contributed to drafting and editing the manuscript. All authors study and approved the final manuscript. Author details 1 Department of Gastroenterology, The Cancer Institute Hospital, Japanese Foundation for Cancer Analysis, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.BuyN-Methyl-3-phenylpropan-1-amine 2Medical Division of Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Investigation, Tokyo, Japan.2,4-Dichloro-5-nitropyrimidine Purity 3Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Analysis, Tokyo, Japan.PMID:35850484 Received: 29 July 2014 Accepted: 9 OctoberConclusion Serum anti-p53 antibody positivity did not predict chemoresistance in mCRC treated with fluoropyrimidine, oxaliplatin, plus bevacizumab at first-line chemotherapy. We think that if we need to know the connection among the anti-p53 antibody status and chemosensitivity, we should really use other methodologies like sequencing, and functional assays, aside from the anti-p53 antibody status.Abbreviations (m)CRC: Metastatic colorectal cancer; IHC: Immunohistochemistry; KRAS:.